VNA
ONCY

Valley National Advisers’s Oncolytics Biotech ONCY Stock Holding History

Valley National Advisers’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.4K Buy
+12,000
New +$11.1K ﹤0.01% 606
2026
Q1 		– Sell
-7,000
Closed -$6K – 925
2025
Q4 		$6K Hold
7,000
– – ﹤0.01% 678
2025
Q3 		$9K Hold
7,000
– – ﹤0.01% 587
2025
Q2 		$5K Buy
7,000
+1,150
+20% +$609 ﹤0.01% 652
2025
Q1 		$3K Buy
+5,850
New +$4.28K ﹤0.01% 687

Other funds holding ONCY

IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
PI
PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.71B AUM 30.33% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
PAS
Professional Advisory Services Vero Beach, Florida $836M AUM 25.79% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Valley National Advisers's ONCY Position: Q2 2026 in Review

Valley National Advisers opened a new position in Oncolytics Biotech (ONCY) in Q2 2026: 12,000 shares worth $11.4K. The stake represents ﹤0.01% of the portfolio and ranks #606 among its holdings. This is a return to the name: Valley National Advisers previously reported a position in ONCY as recently as Q4 2025.

Valley National Advisers first reported a position in ONCY in Q1 2025 and has held it in 5 quarters since. 24 funds tracked by Wall St. Rank hold ONCY as of Q2 2026.

  • Valley National Advisers held 12,000 shares of Oncolytics Biotech worth $11.4K as of Q2 2026.
  • Oncolytics Biotech was a new Valley National Advisers position in Q2 2026.
  • Oncolytics Biotech made up ﹤0.01% of Valley National Advisers's portfolio in Q2 2026, its #606 holding.
  • Valley National Advisers first reported a position in Oncolytics Biotech in Q1 2025 and has held it in 5 quarters since.
  • 24 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q2 2026.

Based on Valley National Advisers's 13F filing for Q2 2026, filed 29 Jul 2026.